Global Microbiome Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Type (FMT v/s Microbiome Drugs), By Application (C. Difficile, Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others), By Region

November 2022 | 114 pages | ID: G49D4651EB5CEN
TechSci Research

Abstracts

The global microbiome therapeutics market is anticipated to witness an impressive growth during the forecast period, 2023-2027. This can be ascribed to the growing prevalence of diseases like phenylketonuria, hepatic encephalopathy, C. difficile infection (CDI), among others and requirement for a precise and faster treatment. This in turn is expected to drive the growth of global microbiome therapeutics market during the forecast period. Additionally, finding therapeutic solutions using microbiome is an emerging field and is attracting the attention of academicians, researchers, and various biotechnology & pharmaceutical companies across the globe. The research, clinical trials related to microbiome therapeutics have significantly increased over the years. According to clinicaltrials.gov, there are around 188 clinical trials registered on its portal related to microbiome therapeutics. This in turn is expected to create lucrative opportunities for the market growth during the forecast period.

Increasing Focus on Human Microbiome Therapeutics Development

The increase prevalence of different types of diseases, failure of current treatment options in providing accurate cure, among others have led to a shift towards alternative therapeutics such as microbiome therapeutics. Being an emerging field, microbiome therapeutics is receiving the attention of research fraternity across the globe. As a result of this a lot of drug discovery and development is happening. As of now there is no approved product and major products are in early stages of clinical trials, in phases I and II. However, companies are advancing their research and may be in the near future an approved microbiome therapeutic product will be available in the market. For instance, in 2021, Seres Therapeutics, Inc. announced data of SER-109, released from its Phase 3 ECOSPOR III study. The pipeline drug is under investigation as an oral therapy for recurring C. difficile infection with an anticipated launch in the first half of 2023.

Growing Funding Activities, Collaborations

The growing collaborations, partnerships, mergers & acquisitions and other strategies followed by various biotechnology & pharmaceutical companies in order to develop a potential microbiome therapeutics is expected to support the market growth in the coming years. For instance, in March 2019, AstraZeneca Plc., collaborated with Seres Therapeutics, Inc. to determine the effect of microbiome environment in a patient undergoing immunotherapy for cancer. Similarly in 2016, AbbVie Inc. entered into a partnership with Synlogic, Inc. for the development of drug for inflammatory bowel disorders. Additionally, increasing funding by different government and non-government organizations across the globe to support research & development activities related to microbiome therapeutics is expected to create lucrative opportunities for the market growth in the next few years. For instance, in 2016, the United States federal government announced USD 121 million for Microbiome Initiative, to provide and coordinate funds for microbiome research.

Market Segmentation

The global microbiome therapeutics market can be segmented into by type, by application, by region, and by company. Based on by type, the market can be divided into FMT and microbiome drugs. Based on application, the market can be categorized into C. Difficile, crohn’s disease, inflammatory bowel disease, diabetes, and others. Regionally, North America dominated the market followed Europe, Asia Pacific, South America and Middle East & Africa. In terms of country, the United States is dominating the overall global microbiome therapeutics market. This can be ascribed to the increasing funding activities in the United States. For instance, the total biotechnology companies funding in the United States stood around USD99.4 billion.

Market Players

4D Pharma plc, Enterome SA, Finch Therapeutics Group, Inc., Vedanta Bioscience, Inc., Seres Therapeutics, Inc., Microbiotica Limited, Destiny Pharma plc, Taisho Pharmaceutical Holdings Co., Ltd., AOBiome Therapeutics, Inc., Ferring Pharmaceuticals SA are some of the leading players operating in the global microbiome therapeutics market.

Report Scope:

In this report, global microbiome therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

• Microbiome Therapeutics Market, By Type:
• FMT
• Microbiome Drugs
• Microbiome Therapeutics Market, By Application:
• C. Difficile
• Crohn’s Disease
• Inflammatory Bowel Disease
• Diabetes
• Others
• Microbiome Therapeutics Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• Asia-Pacific
• China
• India
• Japan
• South Korea
• Australia
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global Microbiome Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. IMPACT OF COVID-19 ON GLOBAL MICROBIOME THERAPEUTICS MARKET

5. VOICE OF CUSTOMER

6. CLINICAL TRIAL ANALYSIS

7. GLOBAL MICROBIOME THERAPEUTICS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Type (FMT v/s Microbiome Drugs)
  7.2.2. By Application (C. Difficile, Crohn’s Disease, Inflammatory Bowel Disease, Diabetes, Others)
  7.2.3. By Region
  7.2.4. By Company (2021)
7.3. Product Market Map

8. NORTH AMERICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Type
  8.2.2. By Application
  8.2.3. By Country
8.3. North America: Country Analysis
  8.3.1. United States Microbiome Therapeutics Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Type
      8.3.1.2.2. By Application
  8.3.2. Mexico Microbiome Therapeutics Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Type
      8.3.2.2.2. By Application
  8.3.3. Canada Microbiome Therapeutics Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Type
      8.3.3.2.2. By Application

9. EUROPE MICROBIOME THERAPEUTICS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Type
  9.2.2. By Application
  9.2.3. By Country
9.3. Europe: Country Analysis
  9.3.1. France Microbiome Therapeutics Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Type
      9.3.1.2.2. By Application
  9.3.2. Germany Microbiome Therapeutics Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Type
      9.3.2.2.2. By Application
  9.3.3. United Kingdom Microbiome Therapeutics Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Type
      9.3.3.2.2. By Application
  9.3.4. Italy Microbiome Therapeutics Market Outlook
    9.3.4.1. Market Size & Forecast
      9.3.4.1.1. By Value
    9.3.4.2. Market Share & Forecast
      9.3.4.2.1. By Type
      9.3.4.2.2. By Application
  9.3.5. Spain Microbiome Therapeutics Market Outlook
    9.3.5.1. Market Size & Forecast
      9.3.5.1.1. By Value
    9.3.5.2. Market Share & Forecast
      9.3.5.2.1. By Type
      9.3.5.2.2. By Application

10. ASIA-PACIFIC MICROBIOME THERAPEUTICS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Type
  10.2.2. By Application
  10.2.3. By Country
10.3. Asia-Pacific: Country Analysis
  10.3.1. China Microbiome Therapeutics Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Type
      10.3.1.2.2. By Application
  10.3.2. India Microbiome Therapeutics Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Type
      10.3.2.2.2. By Application
  10.3.3. South Korea Microbiome Therapeutics Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Type
      10.3.3.2.2. By Application
  10.3.4. Japan Microbiome Therapeutics Market Outlook
    10.3.4.1. Market Size & Forecast
      10.3.4.1.1. By Value
    10.3.4.2. Market Share & Forecast
      10.3.4.2.1. By Type
      10.3.4.2.2. By Application
  10.3.5. Australia Microbiome Therapeutics Market Outlook
    10.3.5.1. Market Size & Forecast
      10.3.5.1.1. By Value
    10.3.5.2. Market Share & Forecast
      10.3.5.2.1. By Type
      10.3.5.2.2. By Application

11. SOUTH AMERICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

11.1. Market Size & Forecast
  11.1.1. By Value
11.2. Market Share & Forecast
  11.2.1. By Type
  11.2.2. By Application
  11.2.3. By Country
11.3. South America: Country Analysis
  11.3.1. Brazil Microbiome Therapeutics Market Outlook
    11.3.1.1. Market Size & Forecast
      11.3.1.1.1. By Value
    11.3.1.2. Market Share & Forecast
      11.3.1.2.1. By Type
      11.3.1.2.2. By Application
  11.3.2. Argentina Microbiome Therapeutics Market Outlook
    11.3.2.1. Market Size & Forecast
      11.3.2.1.1. By Value
    11.3.2.2. Market Share & Forecast
      11.3.2.2.1. By Type
      11.3.2.2.2. By Application
  11.3.3. Colombia Microbiome Therapeutics Market Outlook
    11.3.3.1. Market Size & Forecast
      11.3.3.1.1. By Value
    11.3.3.2. Market Share & Forecast
      11.3.3.2.1. By Type
      11.3.3.2.2. By Application

12. MIDDLE EAST AND AFRICA MICROBIOME THERAPEUTICS MARKET OUTLOOK

12.1. Market Size & Forecast
  12.1.1. By Value
12.2. Market Share & Forecast
  12.2.1. By Type
  12.2.2. By Application
  12.2.3. By Country
12.3. MEA: Country Analysis
  12.3.1. South Africa Microbiome Therapeutics Market Outlook
    12.3.1.1. Market Size & Forecast
      12.3.1.1.1. By Value
    12.3.1.2. Market Share & Forecast
      12.3.1.2.1. By Type
      12.3.1.2.2. By Application
  12.3.2. Saudi Arabia Microbiome Therapeutics Market Outlook
    12.3.2.1. Market Size & Forecast
      12.3.2.1.1. By Value
    12.3.2.2. Market Share & Forecast
      12.3.2.2.1. By Type
      12.3.2.2.2. By Application
  12.3.3. UAE Microbiome Therapeutics Market Outlook
    12.3.3.1. Market Size & Forecast
      12.3.3.1.1. By Value
    12.3.3.2. Market Share & Forecast
      12.3.3.2.1. By Type
      12.3.3.2.2. By Application

13. MARKET DYNAMICS

13.1. Drivers
13.2. Challenges

14. MARKET TRENDS & DEVELOPMENTS

15. COMPETITIVE LANDSCAPE

15.1. 4D Pharma plc
15.2. Enterome SA
15.3. Finch Therapeutics Group, Inc.
15.4. Vedanta Bioscience, Inc.
15.5. Seres Therapeutics, Inc.
15.6. Microbiotica Limited
15.7. Destiny Pharma plc
15.8. Taisho Pharmaceutical Holdings Co., Ltd.
15.9. AOBiome Therapeutics, Inc.
15.10. Ferring Pharmaceuticals SA

16. STRATEGIC RECOMMENDATIONS